Introduction: Breast cancer is the main malignant neoplasm among Brazilian women, and Pará, located in the northern region of Brazil, faces peculiar challenges related to early diagnosis and access to treatment. The analysis of the epidemiological profile of cases in the region is essential to support public policies aimed at prevention, early detection and cancer care. Objectives: To analyze, identify and characterize breast cancer cases in women in the state of Pará from 2020 to 2024. Methods: This is an epidemiological, descriptive, retrospective and quantitative study, with analysis of secondary data extracted from the Brazilian Oncology Panel and the Cancer Information System SISCAN/DATASUS. All breast cancer records (ICD-10: C50) in women living in Pará, diagnosed between 2020 and 2024, were included. The variables analyzed were age, race/color, clinical stage at diagnosis, and time between diagnosis and start of treatment. Results: In the analyzed period (2020–2024), 4,823 cases of breast cancer were diagnosed in women in Pará. The most affected age group was between 50 and 59 years old (37.4%), followed by the 60- to 69-year-old group (28.1%) and 40 to 49 years old (18.9%). Regarding race/color, most women declared themselves to be brown (63%), followed by white (21%) and black (11%). Regarding the clinical stage, 41% of the cases were diagnosed in stage II and 28% in stage III, indicating a predominance of late diagnoses. In addition, 53% of the women started treatment after the recommended period of 60 days, as recommended by Law No. 12,732/2012. Conclusion: Most cases of breast cancer in Pará were diagnosed in intermediate or advanced stages, which compromises the prognosis of patients. The delay in the start of treatment, present in more than half of the cases, highlights weaknesses in the organization of the oncology care network, as well as inequalities in access to diagnostic and treatment services. Previous studies corroborate these findings and highlight that the North region has one of the lowest rates of mammographic screening in the country. Socioeconomic factors, geographic distance from specialized centers, low primary care coverage, and lack of effective prevention campaigns contribute to this scenario. The analysis shows that breast cancer in the state of Pará is mostly diagnosed in advanced stages, with a high proportion of delay in the initiation of treatment. These findings reinforce the need to strengthen screening actions, health education, and organization of the line of cancer care in the state, especially in regions with less access to specialized services.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
